Stock Market Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net… Aditya Bhagchandani Nov 7, 2024
Corporates Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine… News Desk Oct 3, 2024
Stock Market Stocks To Watch Today: Sun Pharma, Alembic Pharma, BEL, Crompton Greaves, and… Markets Desk Mar 27, 2023
Business Alembic Pharma receives USFDA approval for Fulvestrant Injection United News of India (UNI) Dec 26, 2022
